What is Raremark?
Raremark operates as a specialized data-driven platform that bridges the gap between rare disease patient communities and the biopharmaceutical industry. By utilizing machine learning and behavioral science, the company constructs robust research networks that provide pharmaceutical developers with access to anonymized, aggregated patient insights. This unique value proposition addresses critical bottlenecks in clinical trial recruitment and drug development, ultimately aiming to accelerate the speed to market for life-saving therapies. Headquartered in London with a global footprint in Boston, New York, and Ukraine, Raremark is redefining how patient experience is captured and utilized to improve health literacy and medical outcomes.
How much funding has Raremark raised?
Raremark has raised a total of $6.9M across 3 funding rounds:
Private Equity
$1M
Other Financing Round
$2.1M
Series A
$3.8M
Private Equity (2016): $1M, investors not publicly disclosed
Other Financing Round (2018): $2.1M, investors not publicly disclosed
Series A (2018): $3.8M supported by Cass Entrepreneurship Fund, Albion Capital Group, Oltre Venture, and Ananda Ventures
Key Investors in Raremark
Cass Entrepreneurship Fund
A venture capital fund based at Cass Business School that focuses on making commercial equity investments into high-potential, revenue-generating businesses.
Albion Capital Group
A prominent investment firm specializing in providing growth capital to innovative companies across various sectors, with a strong focus on long-term value creation.
Oltre Venture
An impact-focused investment firm that supports early-stage companies aiming to generate both social value and sustainable financial returns.
What's next for Raremark?
With the recent infusion of capital, Raremark is poised to accelerate its strategic roadmap, focusing on the expansion of its patient-centric knowledge base. The company is expected to prioritize the integration of more sophisticated behavioral science models to further increase patient retention and engagement within its research networks. Furthermore, the firm will likely leverage its strengthened balance sheet to forge deeper partnerships with global biopharmaceutical entities, aiming to standardize the use of patient-reported outcomes in regulatory submissions. As the company scales, its ability to maintain data integrity while expanding its reach will be the primary determinant of its long-term market leadership in the rare disease sector.
See full Raremark company page
